Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
Share
Why It Matters
Sagimet tested a new acne medicine on real patients for a full year. The results looked good, and the company raised money to keep going.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.